% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Mengel:279379,
author = {Mengel, David and Soter, Ester and Ott, Julia Maren and
Wacker, Madeleine and Leyva, Alejandra and Peters, Oliver
and Hellmann-Regen, Julian David Nicolai and Schneider,
Luisa-Sophie and Wang, Xiao and Priller, Josef and Spruth,
Eike Jakob and Altenstein, Slawek and Schneider, Anja and
Fliessbach, Klaus and Wiltfang, Jens and Hansen, Niels and
Rostamzadeh, Ayda and Düzel, Emra and Glanz, Wenzel and
Incesoy, Enise I and Buerger, Katharina and Janowitz, Daniel
and Ewers, Michael and Perneczky, Robert and Rauchmann,
Boris Stephan and Teipel, Stefan and Kilimann, Ingo and
Laske, Christoph and Sodenkamp, Sebastian and Spottke,
Annika and Brustkern, Johanna and Brosseron, Frederic and
Wagner, Michael and Stark, Melina and Kleineidam, Luca and
Shao, Kai and Lüsebrink, Falk and Yakupov, Renat and
Schmid, Matthias and Hetzer, Stefan and Dechent, Peter and
Scheffler, Klaus and Berron, David and Jessen, Frank and
Synofzik, Matthis},
collaboration = {group, DELCODE study},
title = {{B}lood biomarkers confirm subjective cognitive decline
({SCD}) as a distinct molecular and clinical stage within
the {NIA}-{AA} framework of {A}lzheimer´s disease.},
journal = {Molecular psychiatry},
volume = {30},
number = {7},
issn = {1359-4184},
address = {[London]},
publisher = {Springer Nature},
reportid = {DZNE-2025-00756},
pages = {3150 - 3159},
year = {2025},
abstract = {Subjective cognitive decline (SCD) is proposed as an
indicator of transitional disease stage 2 in the Alzheimer's
disease (AD) continuum. However, molecular and particularly
longitudinal fluid biomarker data for this stage are still
limited. This study aimed to determine whether blood-based
biomarkers in amyloid-positive individuals with SCD (A +
SCD) support the notion of stage 2 as a distinct stage
between stages 1 and 3 of AD and to identify those at high
risk for clinical progression. In a prospective multicenter
study (DELCODE) involving 457 participants across the AD
continuum, we analyzed plasma phospho-tau 181 (p181) and
neurofilament light chain (NfL) and assessed their
association with longitudinal cognition, hippocampal
atrophy, and AD clinical stage transition. The results
showed that baseline plasma p181 levels were elevated and
increased more rapidly in A + SCD individuals compared to
amyloid-positive cognitively unimpaired (A + CU) individuals
(stage 1). NfL levels rose across A + CU, A + SCD, and
amyloid-positive mild cognitive impairment (A + MCI, stage
3). In A + SCD, but not in A + CU, higher p181 levels
predicted cognitive decline (PACC5) and transition to MCI.
In conclusion, plasma p181 provides molecular biomarker
evidence supporting A + SCD as a pre-dementia AD stage
(stage 2) distinct from A + CU (stage 1) and helps identify
individuals at risk for cognitive decline early in the AD
continuum.},
keywords = {Humans / Cognitive Dysfunction: blood / Cognitive
Dysfunction: diagnosis / Cognitive Dysfunction: metabolism /
Male / Alzheimer Disease: blood / Alzheimer Disease:
metabolism / Female / Biomarkers: blood / Aged /
Neurofilament Proteins: blood / Disease Progression / tau
Proteins: blood / Prospective Studies / Aged, 80 and over /
Amyloid beta-Peptides: blood / United States / Hippocampus:
pathology / Longitudinal Studies / Atrophy /
Neuropsychological Tests / Cognition: physiology / Middle
Aged / Biomarkers (NLM Chemicals) / Neurofilament Proteins
(NLM Chemicals) / neurofilament protein L (NLM Chemicals) /
tau Proteins (NLM Chemicals) / Amyloid beta-Peptides (NLM
Chemicals)},
cin = {AG Gasser / AG Peters / AG Endres / AG Dirnagl / AG Priller
/ AG Schneider / AG Wiltfang / Patient Studies (Bonn) / AG
Düzel / Clinical Research (Munich) / AG Dichgans / AG
Teipel / ICRU / AG Spottke / AG Wagner / AG Heneka / AG
Schmid Bonn / AG Berron / AG Jessen},
ddc = {610},
cid = {I:(DE-2719)1210000 / I:(DE-2719)5000000 /
I:(DE-2719)1811005 / I:(DE-2719)1810002 / I:(DE-2719)5000007
/ I:(DE-2719)1011305 / I:(DE-2719)1410006 /
I:(DE-2719)1011101 / I:(DE-2719)5000006 / I:(DE-2719)1111015
/ I:(DE-2719)5000022 / I:(DE-2719)1510100 /
I:(DE-2719)1240005 / I:(DE-2719)1011103 / I:(DE-2719)1011201
/ I:(DE-2719)1011303 / I:(DE-2719)1013028 /
I:(DE-2719)5000070 / I:(DE-2719)1011102},
pnm = {353 - Clinical and Health Care Research (POF4-353) / 899 -
ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-353 / G:(DE-HGF)POF4-899},
experiment = {EXP:(DE-2719)DELCODE-20140101},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40247130},
pmc = {pmc:PMC12185333},
doi = {10.1038/s41380-025-03021-0},
url = {https://pub.dzne.de/record/279379},
}